Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. - Wikidata - wikimedia - TriplyDB

Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy.

Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy.

http://www.wikidata.org/entity/Q35085027

about

NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS The "two-faced" effects of reactive oxygen species and the lipid peroxidation product 4-hydroxynonenal in the hallmarks of cancer Cellular and molecular mechanisms underlying alcohol-induced aggressiveness of breast cancer CYP1B1 expression promotes the proangiogenic phenotype of endothelium through decreased intracellular oxidative stress and thrombospondin-2 expression Deletion of SPARC Enhances Retinal Vaso-Obliteration in Mouse Model of Oxygen-Induced Retinopathy.Hydroethidine- and MitoSOX-derived red fluorescence is not a reliable indicator of intracellular superoxide formation: another inconvenient truth Reduced nitro-oxidative stress and neural cell death suggests a protective role for microglial cells in TNFalpha-/- mice in ischemic retinopathy.Vascular dysfunction in retinopathy-an emerging role for arginase The quest for selective nox inhibitors and therapeutics: challenges, triumphs and pitfalls NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy.HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy.Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy.Novel role of NADPH oxidase in angiogenesis and stem/progenitor cell function.NAD(P)H oxidase-dependent regulation of CCL2 production during retinal inflammation.Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis)Nanoceria inhibit the development and promote the regression of pathologic retinal neovascularization in the Vldlr knockout mouse Role of IL-6 in angiotensin II-induced retinal vascular inflammation.Role of ROS in ischemia-induced lung angiogenesis Increased expression and activity of 12-lipoxygenase in oxygen-induced ischemic retinopathy and proliferative diabetic retinopathy: implications in retinal neovascularization.12/15-Lipoxygenase-derived lipid metabolites induce retinal endothelial cell barrier dysfunction: contribution of NADPH oxidase Docosahexaenoic acid improves the nitroso-redox balance and reduces VEGF-mediated angiogenic signaling in microvascular endothelial cells.Arginase in retinopathy.Targeting Neovascularization in Ischemic Retinopathy: Recent Advances Organ specific optical imaging of mitochondrial redox state in a rodent model of hereditary hemorrhagic telangiectasia-1 A lipidomic screen of hyperglycemia-treated HRECs links 12/15-Lipoxygenase to microvascular dysfunction during diabetic retinopathy via NADPH oxidase.NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies.Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2 Neuroprotection from retinal ischemia/reperfusion injury by NOX2 NADPH oxidase deletion Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors Constitutive NADPH oxidase 4 activity resides in the composition of the B-loop and the penultimate C terminus Neovascularization in an arterio-venous loop-containing tissue engineering chamber: role of NADPH oxidase.Damaged mitochondrial DNA replication system and the development of diabetic retinopathy.Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line MEF2C ablation in endothelial cells reduces retinal vessel loss and suppresses pathologic retinal neovascularization in oxygen-induced retinopathy Downregulating p22phox ameliorates inflammatory response in Angiotensin II-induced oxidative stress by regulating MAPK and NF-κB pathways in ARPE-19 cells Prediction of diabetic retinopathy: role of oxidative stress and relevance of apoptotic biomarkers.Hyperoxia-Induced Proliferative Retinopathy: Early Interruption of Retinal Vascular Development with Severe and Irreversible Neurovascular Disruption.The twisted survivin connection to angiogenesis eNOS overexpression exacerbates vascular closure in the obliterative phase of OIR and increases angiogenic drive in the subsequent proliferative stage Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy

P2860

Q26821775-200408D0-5A37-4920-B3FF-910C7E74C786 Q28391375-32910FA0-5EF2-4349-AA36-D6263D21E507 Q28397579-944BFF62-5043-4902-9C97-37F6A91ED6F9 Q28592244-EC01FD04-3588-490C-919D-A4B5C2445207 Q30277965-2BAD25D2-CEAE-43A8-A88B-CD7F913B5F01 Q30457642-B78B067B-07DE-41A6-88E5-DF15D9668489 Q33526952-166BDDE5-90AE-4F6B-A958-3BAE18AE5BAE Q33625727-854C0CF4-8B9F-4D36-A301-96F2C6F4AF6C Q33632757-194FBFB4-0ACD-4DB2-8D12-87676C93DE21 Q33632781-0736ACD2-2CD7-4A93-9F3D-33497BA457C6 Q33641974-4FD655E7-B5CC-4F40-8666-7CCD25504B89 Q33641986-5F10D55D-F065-44B9-B393-EF319AD31C95 Q33649852-6A1CB9D9-4532-4FA1-A66B-0A82D4039AAC Q33676913-2C7DFBD1-856C-455C-9EBD-4C652C55A009 Q33787955-2C9426C0-5609-49AD-8B71-17403BCA4567 Q33833925-6FC9680C-E1F9-40A8-88A1-F05A287B5A27 Q33845139-FAD933D8-2C41-4C00-911B-18E318854C50 Q34212717-A5DC6B45-51DE-4756-8D4F-977FEDE28305 Q34527211-783B4033-ACB9-43A8-9F03-71513A7BAD40 Q34600290-4003E8B1-298A-4AB4-ADEE-39FEC212734C Q34662351-D716C663-015D-4F45-97BC-804BC656CA00 Q34800913-F9BA1E3F-2C72-49C9-BA72-AC821A83E5DE Q34972210-3C348B30-3B36-454A-8BBE-9493FD2E952E Q35072955-37E84ED1-D76B-4893-8F74-F9760ECFA06E Q35120919-A2CF3B05-550A-458F-82FE-9562A78C6811 Q35145985-3076E043-E08B-4855-8146-2B5E13C98F2D Q35486123-F09AA040-935A-4DDC-BA0B-7D2B3980817F Q35522186-21322C52-34AD-45DA-9D93-EB6FC089C3F7 Q35824748-74A55094-732C-4654-9146-4D5F2A725BDA Q35841916-92BCCEFE-810E-4C2A-B117-ABD258B6B1BE Q35862506-E7BA8C32-2127-4982-B083-A5F26872A314 Q36001839-4C40D85C-5B84-4AFA-992B-043B7E2B50C3 Q36032332-C1BA2947-8455-4036-B60A-1ABB39795846 Q36044670-41DC3C13-C223-4B02-9371-887F6BB0A451 Q36101886-500F4E67-4F27-46CA-B927-57E37AC07956 Q36117585-3516B018-BE1B-47A1-AE65-1DB395A6BD8F Q36197495-FD0A9C5A-354E-4D9B-94DB-9C88CE202D02 Q36301932-BB55EDAE-CA4F-4E58-B1D0-92B2ABE5CECC Q36302954-5EF15AED-A176-4F15-BCAA-2FA0EF6EF73D Q36379513-F8A4E9A9-24F0-4967-84BC-19A7C3E37656

P2860

Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy.

http://www.wikidata.org/entity/Q35085027

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Inhibition of NAD(P)H oxidase ...... n during ischemic retinopathy.

@ast

Inhibition of NAD(P)H oxidase ...... n during ischemic retinopathy.

@en

type

label

Inhibition of NAD(P)H oxidase ...... n during ischemic retinopathy.

@ast

Inhibition of NAD(P)H oxidase ...... n during ischemic retinopathy.

@en

prefLabel

Inhibition of NAD(P)H oxidase ...... n during ischemic retinopathy.

@ast

Inhibition of NAD(P)H oxidase ...... n during ischemic retinopathy.

@en

P1433

Q35085027-C2509D09-A0B6-407E-B489-3480FF32B020

P1476

Q35085027-299745FE-723F-4CA8-90E8-E9554811BF2E

P2093

Q35085027-1294DAFB-D72B-4055-9F5C-B66BA26F4296

Q35085027-5CEDEF30-774E-49C3-B362-22705C7DA8C1

Q35085027-68FB5FF5-5944-4E98-A5EF-C040265692BB

Q35085027-83F13A37-DE74-4E30-8CFE-ABC4799A88C8

Q35085027-8487527D-2BC1-4A8A-8616-64108E0A253B

Q35085027-BE220C4C-8855-48F9-8D94-D8DEFD185A85

Q35085027-E925131C-B507-4330-8560-ECF70F04BAA2

P2860

Q35085027-0B992B78-2758-4094-B414-5FCB635CC4CB

Q35085027-1D99E2D1-17EA-4337-BAC0-D03B7BC2B432

Q35085027-348FDFB0-7CA0-48CC-8FE1-774A961E85D8

Q35085027-39098762-2ECB-487C-AACE-8EFC4B40A86E

Q35085027-3F0EEFAF-0E2C-4518-8881-13401B3756AD

Q35085027-4152CBE3-CC93-4214-A9D5-5E6387AEB038

Q35085027-4AD6687B-40CF-43F6-A196-33B79CF52E14

Q35085027-4F09087D-BA83-44FB-A86A-B90C126B08EE

Q35085027-5066E8DB-8FA3-433E-AB97-191BFF4187DE

Q35085027-53E7EFF6-3D84-44BF-A2F8-B5C970BCC6AA

P304

Q35085027-4C13E42D-9130-4639-BD44-ABD655EB637F

P31

Q35085027-C484B2BA-2DF3-48A1-BC3B-EA733BBCBBD7

P356

Q35085027-8FA86617-5060-40FE-8868-64AC8A65F3B1

P407

Q35085027-882576F1-DE02-435F-8753-1C5174DF2EBC

P433

Q35085027-F5AA9B72-1D70-4E50-B6E2-D1ADF78E486C

P478

Q35085027-583D6F78-09FE-4B63-A8A7-8BED4D76614E

P50

Q35085027-1D7FE885-96E2-47EE-9568-492172BA07DA

P577

Q35085027-C261C8E0-5417-40B5-A8F2-5DD089D1CEDE

P698

Q35085027-BA741258-FB35-49D8-8B20-B93FF601F7C7

P921

Q35085027-53B3F790-00A4-4B2E-966C-51A7D4B061C5

Q35085027-53EB06DB-AA49-42AD-AEC3-2BB04E88D321

Q35085027-BBA5DFE3-B6D3-4D1C-85CA-C204FCC9E4F4

P932

Q35085027-8A1E475F-DE37-47DC-8321-CB3DA0FC92A7

P356

S0002-9440(10)63001-5

P1433

The American Journal of Pathology

P1476

Inhibition of NAD(P)H oxidase ...... on during ischemic retinopathy

@en

P2093

Daniel H Platt

http://www.w3.org/2001/XMLSchema#string

M Ali Behzadian

http://www.w3.org/2001/XMLSchema#string

Manuela Bartoli

http://www.w3.org/2001/XMLSchema#string

Mohamed Al-Shabrawey

http://www.w3.org/2001/XMLSchema#string

Robert W Caldwell

http://www.w3.org/2001/XMLSchema#string

Ruth B Caldwell

http://www.w3.org/2001/XMLSchema#string

Sue Matragoon

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a cytochrome b-type NAD(P)H oxidoreductase ubiquitously expressed in human cells

NADPH oxidase is an O2 sensor in airway chemoreceptors: evidence from K+ current modulation in wild-type and oxidase-deficient mice

Hyperglycemia increases mitochondrial superoxide in retina and retinal cells

Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis

The biology of vascular endothelial growth factor

The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases.

Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice.

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.

NADPH oxidase: a universal oxygen sensor?

Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.

P304

599-607

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0002-9440(10)63001-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

167

http://www.w3.org/2001/XMLSchema#string

P50

Azza B El-Remessy

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16049343

http://www.w3.org/2001/XMLSchema#string

P921

neovascularization

P932

1603550

http://www.w3.org/2001/XMLSchema#string